225. Efficacy and safety of sulbactam-durlobactam are consistent across regions in the global ATTACK phase 3 trial in the treatment of carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) infections

作者
Alita A. Miller,Adam B. Shapiro,Sarah M. McLeod,Khurram Z. Rana,Drew E. Lewis,David Altarac
出处
期刊:Open Forum Infectious Diseases [Oxford University Press]
卷期号:9 (Supplement_2) 被引量:1
标识
DOI:10.1093/ofid/ofac492.303
摘要

Abstract Background ATTACK is a randomized, active-controlled, noninferiority trial that evaluated the efficacy and safety of sulbactam-durlobactam (SUL-DUR) compared to colistin for CRABC infections. The primary efficacy endpoint of all-cause mortality (ACM) at day 28 and the primary safety objective of incidence of nephrotoxicity based on RIFLE criteria were met. Due to the global variation of carbapenem and multi-drug resistance, geographic subgroups were evaluated to explore consistency of efficacy and safety across regions. Methods Patients were randomized to SUL-DUR or colistin treatment for 7-14 days and all patients received imipenem/cilastatin as background therapy. The primary efficacy analysis in the CRABC population consisted of 125 patients: SUL-DUR (N=63) and colistin (N=62). The primary safety population included 177 patients who received any amount of drug. Secondary efficacy endpoints included ACM at day 14, clinical cure and microbiological favorable assessment at end-of treatment (EOT), test-of-cure (TOC) and late follow-up (LFU). Results are described geographically by the following regions: the Americas, Asia-Pacific and Europe. Results Overall, ACM at day 28 in the SUL-DUR arm and colistin arm was 12/63 (19.0%) vs. 20/62 (32.3%), respectively; ACM at day 14 overall in the SUL-DUR arm and colistin arm was 4/63 (6.3%) vs. 12/62 (19.4%), respectively (Table 1). Day 28 ACM, and secondary endpoints were similar across the geographic regions and consistent with overall findings (Table 1). Criteria for RIFLE nephrotoxicity were met more often in the colistin arm than the SUL-DUR arm in all regions (Table 1). Conclusion ACM, clinical outcomes, microbiological favorable assessment, and RIFLE-assessed nephrotoxicity were consistently favorable in patients treated with SUL-DUR versus colistin across regions. These findings suggest, that if approved, SUL-DUR could be an important global therapeutic option for Acinetobacter infections including carbapenem-resistant and multidrug-resistant strains. Disclosures Alita Miller, PhD, Entasis Therapeutics: Ownership Interest|Entasis Therapeutics: Stocks/Bonds Adam B. Shapiro, Ph.D, Entasis Therapeutics: Employee|Entasis Therapeutics: Stocks/Bonds Sarah McLeod, PhD, Entasis Therapeutics: Employee|Entasis Therapeutics: Stocks/Bonds Khurram Rana, PharmD, Entasis Therapeutics: Employee|Entasis Therapeutics: Ownership Interest|Entasis Therapeutics: Stocks/Bonds Drew Lewis, MD, MTM&H, Entasis Therapeutics: employee|Entasis Therapeutics: employee|Entasis Therapeutics: Stocks/Bonds|Entasis Therapeutics: Stocks/Bonds David Altarac, MD, MPA, Entasis Therapeutics: Ownership Interest|Entasis Therapeutics: Stocks/Bonds.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
颖小轩给颖小轩的求助进行了留言
刚刚
55发布了新的文献求助10
刚刚
king完成签到,获得积分10
刚刚
Hello的应助被hikki采纳,获得10
1秒前
Lymtics完成签到,获得积分10
1秒前
现代半莲完成签到,获得积分10
1秒前
周周完成签到,获得积分10
1秒前
1秒前
羽言完成签到,获得积分10
1秒前
落后十八发布了新的文献求助20
2秒前
2秒前
端午完成签到,获得积分10
2秒前
雪流星完成签到 ,获得积分10
2秒前
震动的葶完成签到,获得积分10
2秒前
Yu完成签到,获得积分10
2秒前
hedinghong完成签到,获得积分10
2秒前
2秒前
XU2025完成签到 ,获得积分10
2秒前
kokuyomax完成签到,获得积分10
2秒前
lu10完成签到,获得积分10
3秒前
Irene完成签到,获得积分10
3秒前
青春纯白色完成签到,获得积分10
3秒前
积极毛巾完成签到,获得积分10
4秒前
Spark完成签到,获得积分10
4秒前
5秒前
haoyooo完成签到,获得积分10
5秒前
柚子皮完成签到,获得积分10
5秒前
瑩火虫完成签到 ,获得积分10
5秒前
苹果完成签到 ,获得积分10
5秒前
瘦瘦熊猫完成签到,获得积分10
5秒前
何文艺完成签到,获得积分10
6秒前
苹果王子6699完成签到 ,获得积分0
6秒前
美女发布了新的文献求助10
6秒前
asss完成签到,获得积分10
6秒前
oioi发布了新的文献求助10
6秒前
6秒前
wyy完成签到,获得积分10
6秒前
你看远山含笑水流长完成签到,获得积分10
6秒前
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173729
求助须知:如何正确求助?哪些是违规求助? 9565870
关于积分的说明 21782999
捐赠科研通 7767898
什么是DOI,文献DOI怎么找? 3431625
关于科研通互助平台的介绍 2555879
邀请新用户注册赠送积分活动 2476903